Clairity, Inc. is a pioneering digital health company founded in 2020 and headquartered in Boston, Massachusetts. The company is dedicated to transforming cancer risk assessment by leveraging artificial intelligence (AI) and deep learning technologies. Its mission is to shift the standard of care from reactive diagnosis to proactive prevention, ensuring that individuals, regardless of race, ethnicity, or gender, have access to comprehensive health risk information.
Clairity's strategic focus centers on enhancing early detection and personalized care in oncology through AI-driven solutions. The company's flagship product, CLAIRITY BREAST, is an FDA-authorized AI platform that analyzes mammographic imaging data to predict a woman's five-year risk of developing breast cancer. This platform integrates seamlessly into existing clinical workflows, enabling healthcare providers to offer personalized care plans based on individual risk assessments.
In October 2022, Clairity secured $6.67 million in a Series B funding round, bringing its total funding to approximately $10.5 million. The primary investor in this round was Santé Ventures. The capital is intended to support the commercialization of CLAIRITY BREAST and further development of the company's AI-driven healthcare solutions.
CLAIRITY BREAST is a mammography-based AI platform designed to predict a woman's five-year risk of developing breast cancer. The AI model was trained on millions of mammogram images, matched with five-year outcome data, to identify patterns in breast tissue that correlate with future cancer development. The platform received FDA De Novo authorization in May 2025, marking a significant milestone in AI-driven healthcare solutions.
Clairity's technological platform is distinguished by its proprietary AI algorithms capable of analyzing imaging data at the pixel level to uncover subtle patterns invisible to the human eye. This approach enhances risk prediction accuracy and supports personalized patient care. The company's AI models are trained on diverse datasets to ensure equitable risk assessments across different populations.
Leadership Team:
- Constance "Connie" Lehman, MD, PhD: Founder. Dr. Lehman is a breast imaging specialist at Mass General Brigham and a professor of radiology at Harvard Medical School. She has extensive experience in breast cancer research and imaging.
- Jeff Luber: Chief Executive Officer. Appointed in 2025, Luber brings experience in oncology, genetic sequencing, infectious disease testing, and digital health. He is responsible for guiding Clairity through market launch and global expansion.
- Philippe Raffy: Chief Technology Officer. Raffy leads the technological development and implementation of Clairity's AI platforms.
- Merle Waterman: Chief Financial Officer. Waterman oversees the company's financial strategy and operations.
- Shriram Narayanan: Software Engineering Manager. Narayanan manages the software development team, ensuring the robustness and scalability of Clairity's platforms.
Board of Directors:
- Kevin Lalande: Co-Founder and Managing Director at Santé Ventures. Lalande provides strategic guidance and investment oversight.
- Joe Cunningham, MD: Managing Director at Santé Ventures. Dr. Cunningham offers insights into healthcare investment and strategy.
- Gabriella Antici, MS: Founder of Protea Institute. Antici brings expertise in healthcare management and innovation.
In 2025, Clairity appointed Jeffrey R. Luber as Chief Executive Officer, succeeding Caroline Reeuwijk. Luber's extensive experience in healthcare leadership is expected to drive the company's global expansion and commercialization efforts.
Market Insights and Dynamics:
The global breast cancer prediction market is valued at approximately $63 billion, with significant growth potential driven by advancements in AI and personalized medicine. The increasing incidence of breast cancer and the demand for early detection solutions underscore the market's expansion.
Competitor Analysis:
Key competitors in the AI-driven breast cancer risk assessment space include:
- iCAD, Inc.: Offers AI solutions for breast cancer detection and risk assessment.
- Hologic, Inc.: Provides mammography systems with integrated AI capabilities.
- Kheiron Medical Technologies: Develops AI tools for breast cancer detection and risk prediction.
These companies focus on enhancing early detection and personalized care through AI technologies, contributing to a competitive landscape in the breast cancer risk assessment market.
Clairity has established significant collaborations to strengthen its market position and innovation capacity. The company formed the Clairity Consortium, partnering with academic and community centers, including the German Mammography Screening Program, to train and validate its AI models on diverse datasets.
Clairity's strategic considerations include leveraging its FDA-authorized platform to gain a competitive advantage in the breast cancer risk assessment market. The company's focus on equitable and personalized risk prediction positions it distinctively among competitors. Additionally, Clairity's seamless integration into existing clinical workflows enhances its appeal to healthcare providers.
Looking ahead, Clairity aims to expand the adoption of CLAIRITY BREAST across leading health systems globally. The company plans to invest in further research and development to enhance its AI models and explore additional applications in oncology risk assessment. Clairity's commitment to proactive prevention and personalized care positions it to capitalize on emerging opportunities in the healthcare AI sector.
Contact Information:
- Website: www.clairity.com
- LinkedIn: Clairity LinkedIn Profile
- Headquarters: Boston, Massachusetts, United States
